Vera Therapeutics Adds Experienced Legal Chief As Shares Trade Below Targets
Vera Therapeutics has appointed Jane Wright-Mitchell as its new Chief Legal Officer, bringing extensive legal and compliance experience to the company. This leadership change occurs as VERA shares trade below analyst targets and its estimated fair value, with mixed short-term returns but strong long-term growth. The appointment is significant for managing legal risks, partnerships, and intellectual property, especially for a clinical-stage biotech.
Point72 (NASDAQ: VERA) reports 1.7% holding, 1.23M shares disclosed
Point72-affiliated entities have reported a 1.7% beneficial stake in Vera Therapeutics (NASDAQ: VERA), totaling 1,229,525 shares as of March 31, 2026. This holding includes 17,800 shares exercisable from call options. The Schedule 13G filing indicates a passive investment intent, with shared voting and dispositive power among Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen.
Is Vera Therapeutics (VERA) Pricing Reflect Its DCF Upside After Recent Share Price Weakness
Vera Therapeutics (VERA) has experienced recent stock price weakness but shows significant long-term returns. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 88.5%, with an intrinsic value of about US$338.10 per share compared to its current price of US$38.86. However, its Price-to-Book ratio of 4.59x is above the biotech industry average, indicating it's about right by that metric.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Vera Therapeutics (VERA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights key events like clinical trial data, financing transactions, and governance changes, with AI-powered summaries to help investors quickly parse crucial information. The article also details recent Form 144 sales and insider equity awards for executives.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to Jane Wright-Mitchell, its new Chief Legal Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards include non-qualified stock options for 56,850 shares and restricted stock units (RSUs) for 42,403 shares of Class A common stock. The stock options have an exercise price of $40.73 and will vest over four years, while the RSU award will also vest over four years.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to Jane Wright-Mitchell, its new Chief Legal Officer, consisting of non-qualified stock options and restricted stock units. These awards were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for her employment. The stock options and RSUs have specific vesting schedules over four years, contingent on her continued service.
New Vera legal chief gets 56,850 options and 42,403 RSUs
Vera Therapeutics (NASDAQ: VERA) has granted inducement equity awards to its new Chief Legal Officer, Jane Wright-Mitchell, consisting of 56,850 non-qualified stock options and 42,403 restricted stock units (RSUs). These awards, approved on March 23, 2026, are part of the company's 2024 Inducement Plan and vest over four years, aligning with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $40.73, matching Vera's closing price on the grant date.
Vanguard disaggregates holdings; Vera Therapeutics (VERA) shows 0 shares reported
Vanguard has amended its Schedule 13G/A for Vera Therapeutics (VERA) to report 0 shares beneficially owned, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately, relying on SEC Release No. 34-39538. This procedural amendment indicates a change in Vanguard's reporting structure rather than a complete divestment, as subsidiary holdings will be disclosed independently.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Vera Therapeutics (VERA) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. It highlights key events such as sales agreements, public offerings, clinical trial updates (like the ORIGIN Phase 3 trial for atacicept), corporate governance changes, and financial reports. The platform, Stock Titan, offers AI-powered summaries to help investors quickly understand the content of these regulatory documents.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of Vera Therapeutics, Inc.'s SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors tracking the company's financial and operational developments. It details recent filings like equity awards for executives, ownership disclosures by institutional investors, and announcements regarding fundraising for the potential launch of its lead drug, atacicept. The platform offers AI-powered summaries to help users quickly understand key points from these regulatory documents.
VERA SEC Filings - Vera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Vera Therapeutics, Inc. (VERA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights the company's regulatory disclosures related to clinical milestones, financing, governance changes, and key events like at-the-market offerings and clinical trial data. The platform also offers AI-powered summaries and access to insider transaction details, crucial for investors tracking the biotechnology company's progress in immunological diseases.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as its Chief Legal Officer, effective immediately. With over 25 years of experience in business and compliance law, Wright-Mitchell will leverage her expertise in regulatory approvals, commercialization, and intellectual property as the company prepares for the potential launch of its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy. Her experience previously as a strategic legal consultant for Vera Therapeutics and her background as General Counsel at Vaxcyte highlight her readiness for this significant role.
Equity grants to Vera Therapeutics (VERA) Chief Legal Officer detailed in Form 4
Vera Therapeutics' Chief Legal Officer, Jane Wright-Mitchell, received new equity awards comprising a stock option for 56,850 shares at an exercise price of $40.73 and 42,403 restricted stock units (RSUs). These grants are part of the company's compensation plan, with multi-year vesting schedules designed for retention and alignment with long-term company performance, rather than reflecting immediate stock market expectations. The awards are not open-market purchases or sales and were granted under the 2024 Inducement Plan.
Assessing Vera Therapeutics (VERA) Valuation As Price To Book And DCF Send Mixed Signals
Vera Therapeutics (VERA) is facing mixed valuation signals, with a Price-to-Book ratio of 4.7x suggesting it is overvalued compared to its peers and the biotech industry average, mainly due to its clinical stage and lack of revenue. However, a Discounted Cash Flow (DCF) model indicates the stock is trading at a significant discount (88.1%). Investors are urged to consider these conflicting signals and assess the inherent risks, including trial outcomes and ongoing losses, before making investment decisions.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, bringing over 25 years of legal experience in the life sciences sector. Her expertise will be crucial as the company progresses towards the potential launch of its dual BAFF/APRIL inhibitor, atacicept, for IgA nephropathy. The company aims to advance treatments for serious immunological diseases and holds global developmental and commercial rights to its key product candidates.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics has appointed Jane Wright-Mitchell as its new Chief Legal Officer. Ms. Wright-Mitchell, who previously served as a strategic legal consultant for the company, brings over 25 years of experience in business and compliance law within the life sciences industry. Her expertise will be crucial as Vera Therapeutics advances towards the potential launch of its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics, Inc. (Nasdaq: VERA) announced the immediate appointment of Jane Wright-Mitchell, Pharm.D., J.D., as its new Chief Legal Officer. Ms. Wright-Mitchell brings over 25 years of legal experience in the life sciences industry and will play a crucial role as Vera Therapeutics approaches the potential commercial launch of atacicept, its lead product candidate for IgA nephropathy. Her expertise in regulatory approvals, commercialization, and intellectual property management is expected to strengthen the company’s foundation for future success.
Investment Firm Boosts Vera Therapeutics Holding to $41.75M in 2026 - News and Statistics
Integral Health Asset Management expanded its stake in Vera Therapeutics by acquiring 100,000 shares valued at $3.55 million in February 2026, increasing its total holding to $41.75 million. This move comes as Vera Therapeutics, a clinical-stage biotech company, awaits a key FDA regulatory decision in July for its lead drug candidate, which has reported positive Phase 3 trial results. The company, which specializes in therapies for immunological diseases, finished the previous year with significant cash reserves, positioning it for commercialization efforts.
Vera Therapeutics (VERA) finance chief exercises options for 10,000 shares
Joseph R. Young, Vera Therapeutics' SVP of finance and chief accounting officer, exercised stock options to acquire 10,000 shares of Class A common stock at $3.9396 per share on March 13, 2026. Following this transaction, he directly owns 75,754 shares and holds 38,589 stock options. The filing indicates that 1,032 of his shares were obtained through the company's 2021 Employee Stock Purchase Plan, and the stock options vest over time.
Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears
Deerfield Management Company has increased its stake in Vera Therapeutics (VERA) as the FDA priority review for its lead drug candidate, atacicept, approaches. Despite Vera's current losses, Simply Wall St's discounted cash flow (DCF) model suggests a significant undervaluation at $337.43 per share compared to its current price of $39.96, driven by strong growth forecasts. However, the company's price-to-book ratio is higher than peers, indicating a mixed valuation picture that warrants further investigation by investors.
Deep Track files 13G disclosing 5.50% stake in Vera Therapeutics (NASDAQ: VERA)
Deep Track Capital, LP and Deep Track Biotechnology Master Fund, Ltd. have filed a Schedule 13G, disclosing a beneficial ownership of 3,921,362 shares in Vera Therapeutics (NASDAQ: VERA). This represents a 5.50% stake in the company's Class A common stock, based on 71,355,667 shares outstanding as of February 23, 2026. David Kroin is identified as a control person for the Deep Track entities, holding shared voting and dispositive power over these shares.
Christopher Hite joins Vera Therapeutics (NASDAQ: VERA) board of directors
Vera Therapeutics (NASDAQ: VERA) announced the appointment of Christopher Hite to its board of directors as a Class III director, effective March 5, 2026. His initial term extends to the 2027 annual stockholders’ meeting, and his compensation aligns with the company's non-employee director policy. Hite received a stock option for 24,937 shares at an exercise price of $38.85, vesting monthly over three years, and will receive an annual cash retainer of $45,000, pro-rated for 2026.
Vera Therapeutics appoints Christopher Hite to Board as Class III Director
Vera Therapeutics (VERA) has appointed Christopher Hite to its Board of Directors as a Class III Director, effective March 5, 2026. Hite will be eligible for a nonstatutory option to purchase 24,937 shares and will receive an annual cash retainer of $45,000, pro-rated for 2026. This information is based on an SEC 8-K filing from March 9, 2026.
Vera Therapeutics Adds Christopher Hite to Board
Vera Therapeutics (VERA) has appointed Christopher Hite as a Class III director to its board, with his term ending in 2027. Hite received stock options and cash compensation, with future equity awards planned under standard independent board practices. Despite accelerating losses and cash burn, Spark’s AI Analyst rates VERA as Neutral due to a strong balance sheet and a recent equity raise cushioning financial flexibility.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement awards granted to six new employees under its 2024 Inducement Plan. These awards, approved by the Compensation Committee, consist of non-qualified stock options to purchase 46,000 shares and restricted stock units underlying 25,875 shares of Class A common stock. The grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new employees, with vesting periods set over four years.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement grants on March 3, 2026, consisting of non-qualified stock options for 46,000 shares and restricted stock units for 25,875 shares, issued to six new employees. These awards, approved by the Compensation Committee, are designed as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4) and are subject to vesting schedules over four years. The stock options have an exercise price matching the closing trading price on the grant date, and the RSUs' vesting commencement dates vary based on the employee's start date.
Six new Vera Therapeutics hires receive 4-year stock awards
Vera Therapeutics announced it granted inducement awards to six new employees on March 3, 2026, under its 2024 Inducement Plan. These awards consist of 46,000 non-qualified stock options with an exercise price of $39.30 and 25,875 restricted stock units (RSUs). Both the options and RSUs will vest over four years, with a 25% initial vest after one year and the remainder monthly or annually, subject to continued employment.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement grants on March 3, 2026, to six new employees, consisting of stock options and restricted stock units. These awards were made under the company's 2024 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4), and are subject to multi-year vesting schedules contingent on continued employment. The move aims to attract and retain talent for the biotechnology firm focused on developing treatments for immunological diseases.
Vera Therapeutics Appoints Christopher Hite to Board of Directors
Vera Therapeutics, Inc. has appointed Christopher Hite, an experienced biopharmaceutical executive, to its Board of Directors. Hite's extensive background in corporate and financial strategy, including roles at Royalty Pharma, Citi, and Lehman Brothers, is expected to support Vera Therapeutics as it prepares for the potential launch of its lead product candidate, atacicept, for IgA nephropathy. This appointment aims to strengthen the company's leadership during a critical growth phase.
Vera Therapeutics Appoints Christopher Hite to Board of Directors
Vera Therapeutics has appointed Christopher Hite to its Board of Directors, bringing extensive corporate and financial strategy expertise to the company. This move is timed as Vera Therapeutics prepares for the launch of its lead product candidate, atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy. Hite's experience from Royalty Pharma and Citi, along with his board memberships, is expected to significantly contribute to the company's strategic growth and goal of addressing unmet medical needs in autoimmune diseases.
Assessing Vera Therapeutics (VERA) Valuation After FDA Priority Review And Phase 3 IgAN Success
Vera Therapeutics (VERA) is under valuation scrutiny after its lead drug, atacicept, received FDA priority review following positive Phase 3 data for IgA nephropathy. Despite recent share price declines, the company shows significant long-term momentum, though it remains unprofitable. Simply Wall St's analysis indicates a high Price-to-Book ratio of 4.8x suggesting overvaluation, yet a Discounted Cash Flow (DCF) model indicates the stock might be trading at an 81% discount to its estimated future value, prompting investors to consider if the market is overly discounting potential risks and future growth.
Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)
Vera Therapeutics (VERA) reported a significant net loss for 2025 but has garnered positive Phase 3 data for its drug atacicept in IgA nephropathy and received FDA priority review with a PDUFA date of July 7, 2026. The company anticipates current funds will cover operations through potential drug approval and U.S. commercial launch. While the promising clinical data and FDA review could be transformative, the company faces risks related to substantial losses, single-drug dependence, and potential financing needs.
Vera Therapeutics (VERA) widens 2025 loss as atacicept wins FDA priority review
Vera Therapeutics reported a wider net loss of $299.6 million in 2025 due to increased R&D and administrative expenses, compared to a $152.1 million loss in 2024. Despite the loss, the company secured significant funding, ending 2025 with $714.6 million in cash, supplemented by $800 million from equity and debt financings, which is expected to support operations past the potential U.S. launch of atacicept. The FDA granted priority review to atacicept for IgA nephropathy, with a PDUFA date of July 7, 2026, and the company anticipates a mid-2026 commercial launch if approved, based on positive Phase 3 clinical trial data.
Vera Therapeutics (VERA) CMO executes mandated sell-to-cover stock transaction
Vera Therapeutics' Chief Medical Officer, Robert Brenner, executed a mandated "sell-to-cover" transaction, selling 2,151 shares of Class A Common Stock at a weighted-average price of $41.9839 per share. This sale was non-discretionary and required to satisfy tax withholding obligations arising from the vesting of restricted stock units. After the transaction, which occurred between February 23 and 24, 2026, Brenner retained ownership of 50,947 shares.
Tax-driven stock sale by Vera Therapeutics (NASDAQ: VERA) CFO
Vera Therapeutics, Inc.'s CFO, Sean Grant, conducted a mandated "sell-to-cover" transaction, selling 4,949 shares of Class A common stock at a weighted-average price of $41.9839 per share. This sale was explicitly stated to satisfy tax withholding obligations from vesting restricted stock units and was not a discretionary sale. Following this transaction, Grant directly owns 114,181 shares and indirectly holds 5,000 shares through a trust.
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity
Vera Therapeutics CEO Marshall Fordyce completed a mandatory "sell-to-cover" transaction, disposing of 16,925 Class A common shares at a weighted-average price of $41.9839 to satisfy tax obligations tied to restricted stock unit vesting. The transactions, executed between February 23 and February 24, 2026, were non-discretionary. Following the sale, Fordyce directly holds 257,163 shares, with additional indirect holdings through a GRAT and a trust.
Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)
JPMorgan and Cantor Fitzgerald have reiterated Overweight ratings on Vera Therapeutics (VERA), citing the potential approval of atacicept for IgA-related kidney disorder as a key driver. Both firms foresee significant upside potential for the stock, with price targets ranging from $96 to $100. Vera Therapeutics, a late-stage clinical biotechnology company, is also developing MAU868 for BK viremia infections.
Vera Therapeutics, Inc. (VERA): A Bull Case Theory
This article summarizes a bullish thesis on Vera Therapeutics (VERA), highlighting its lead asset, atacicept, for IgA nephropathy (IgAN). Atacicept, a de-risked therapy with strong Phase 3 data, addresses a substantial market with potential peak annual revenues of $1.5–$2.5 billion. Despite recent positive developments and regulatory progress, the stock is considered undervalued, presenting a compelling investment opportunity.
Vera Therapeutics, Inc. (VERA): A Bull Case Theory
Vera Therapeutics (VERA) presents a compelling bull case centered on its lead asset, atacicept, for IgA nephropathy (IgAN). With an estimated $10 billion U.S. total addressable market and strong Phase 3 data, atacicept is expected to achieve blockbuster status and begin commercialization in mid-2026. Despite recent positive developments, the stock appears undervalued, offering significant upside potential and making it an attractive acquisition target for larger pharmaceutical companies.
Assessing Vera Therapeutics (VERA) Valuation As Atacicept Nears FDA Decision And Commercial Leadership Shifts
Vera Therapeutics (VERA) is at a pivotal point with its lead drug, atacicept, undergoing FDA Priority Review and a new Chief Commercial Officer appointed. Despite a recent share price decline, Simply Wall St's DCF model suggests the stock is significantly undervalued at $40.95 compared to a fair value of $248.55, though its P/B ratio appears high relative to the industry. Investors are advised to consider clinical risks, funding needs, and future profitability alongside these valuation metrics.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted to two new employees on February 2, 2026, under its 2024 Inducement Plan. These awards, approved by the Compensation Committee, include non-qualified stock options to purchase 11,500 shares and restricted stock units (RSUs) underlying 5,750 shares, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $45.28 and both options and RSUs will vest over four years, contingent on continued employment.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement grants of non-qualified stock options and restricted stock units to two new employees on February 2, 2026. These awards, consisting of 11,500 stock options and 5,750 RSUs, were approved by the Compensation Committee as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4). The grants have specific vesting schedules over four years, contingent on continued employment with the company.
Two new Vera Therapeutics hires get stock options and 4-year RSUs
Vera Therapeutics (Nasdaq: VERA) announced inducement awards to two new employees under its 2024 Inducement Plan. The awards include non-qualified stock options for 11,500 shares and restricted stock units (RSUs) for 5,750 shares, both vesting over four years. These grants were made on February 2, 2026, with the stock options having an exercise price of $45.28 per share, matching the closing price on that date.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement grants on February 6, 2026, consisting of non-qualified stock options and restricted stock units, to two new employees. These awards were made under the company's 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4), to incentivize new hires. The stock options and RSUs will vest over four years, subject to continued employment, with specific vesting schedules and an exercise price based on the closing trading price on February 2, 2026.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to two new employees on February 2, 2026, under its 2024 Inducement Plan. These awards, approved by the Compensation Committee, consist of non-qualified stock options and restricted stock units, designed to incentivize their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $45.28 and both the options and RSUs will vest over four years, subject to continued employment.
Is Vera’s New Commercial Chief for Atacicept Reshaping the Investment Case for Vera Therapeutics (VERA)?
Vera Therapeutics recently appointed Matt Skelton as Chief Commercial Officer to lead the potential launch of its drug candidate, atacicept, for IgA nephropathy, signaling the company's focus on commercialization ahead of an upcoming FDA decision. Skelton's extensive experience in drug launches at previous companies underscores Vera's strategic shift from a clinical-stage company to a commercial entity. While the FDA ruling on July 7, 2026, remains a key catalyst, investors should be aware of the risks associated with regulatory outcomes, potential future dilution, and the company's single-asset pipeline.
Vera Therapeutics Adds CCO As Atacicept Advances And Valuation Gap Persists
Vera Therapeutics has appointed Matt Skelton as Chief Commercial Officer, a strategic move as the company prepares for the potential commercialization of its lead drug, atacicept, for IgA nephropathy. The drug has received Breakthrough Therapy Designation, and the new hire signals a shift towards go-to-market planning. Despite recent negative momentum in its stock price, Vera Therapeutics shares trade significantly below analyst targets and estimated fair value, indicating a wide valuation gap.
Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential?
Vera Therapeutics (VERA) is highlighted as a top high short-interest stock with significant upside potential. This comes after Bank of America and Goldman Sachs raised their price targets due to increased revenue forecasts for its lead IgAN drug and expanded market opportunity. Despite its potential, the article suggests specific AI stocks might offer better upside with less risk.
Biotech Vera taps launch veteran Matt Skelton to ready IgAN drug
Vera Therapeutics has appointed Matt Skelton as its Chief Commercial Officer, effective January 28, 2026. Skelton, who previously served as Executive Vice President, Commercial, will lead the launch readiness efforts for atacicept, the company's investigational drug for IgA nephropathy. His extensive background includes scaling Seagen's commercial organization and holding senior commercial roles at Amgen and Eli Lilly, providing critical experience as Vera Therapeutics prepares to transition into a commercial-stage company.
Assessing Vera Therapeutics (VERA) Valuation After Phase Three Success And AI Drug Discovery Progress
Vera Therapeutics (VERA) is gaining investor attention following successful phase three kidney disease trial results and advancements in AI-enabled drug discovery. Despite a recent short-term decline, the stock has shown significant long-term growth, with its current P/B ratio at 8.4x, much higher than the biotech industry average. However, a Discounted Cash Flow (DCF) model suggests the stock is trading at a significant discount to its estimated future value per share.
